A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

• Status: Completed
• Trial end date: 2017-01-31
• Target enrollment: 0
• Participant gender: All

Summary

This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. Participants received daily oral doses of 150 mg Tarceva. The anticipated time on study treatment was 12 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Adult patients, >/=18 years of age

• Locally advanced or metastatic non-small cell lung cancer

• Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Life expectancy over >/=12 weeks

• Adequate hematological, liver, or kidney function

Exclusion Criteria:

• Previous therapy against epidermal growth factor receptor for metastatic disease

• Treatment with investigational drug during the 3 weeks before enrollment

• History of neoplasm

• Patients with symptomatic cerebral metastases

• Unstable systemic disease